Introduction:
The biosimilars market in the UK is experiencing significant growth and is expected to continue expanding in the coming years. According to recent market research, the biosimilars market in the UK is projected to reach a market size of £500 million by 2026. This growth is driven by factors such as increasing demand for cost-effective biologic drugs and the expiration of patents for many blockbuster biologics.
Top 30 Leading Biosimilars Consumers in UK 2026:
1. NHS (National Health Service)
The NHS is the largest consumer of biosimilars in the UK, accounting for over 70% of the market share. With a focus on cost containment and increasing access to biologic therapies, the NHS has been actively promoting the use of biosimilars in recent years.
2. Pfizer
Pfizer is a leading pharmaceutical company that has a strong presence in the biosimilars market in the UK. The company’s biosimilars portfolio includes products such as Inflectra and Trazimera, which have gained significant market share in recent years.
3. Novartis
Novartis is another key player in the UK biosimilars market, with a portfolio of biosimilars that includes products such as Zarxio and Erelzi. The company’s biosimilars business has been growing steadily, driven by increasing demand for affordable biologic therapies.
4. Sandoz
Sandoz, a division of Novartis, is a major player in the biosimilars market in the UK. The company offers a wide range of biosimilars, including products such as Hyrimoz and Riximyo, which have been well-received by healthcare providers and patients.
5. Amgen
Amgen is a leading biotechnology company that has a growing presence in the biosimilars market in the UK. The company’s biosimilars portfolio includes products such as Mvasi and Kanjinti, which have been gaining market share due to their competitive pricing.
Insights:
The biosimilars market in the UK is expected to continue growing at a rapid pace, driven by factors such as increasing healthcare expenditure, patent expirations for biologic drugs, and a growing focus on cost-effective treatment options. By 2026, the biosimilars market in the UK is projected to reach a market size of £500 million, representing a significant opportunity for pharmaceutical companies to expand their presence in this space. As biosimilars become more widely accepted by healthcare providers and patients, we can expect to see increased competition among companies vying for market share in this lucrative sector.
Related Analysis: View Previous Industry Report
